Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological
 outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral
 treatment
Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis
 C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could
 predict virological outcome in HCV-infected patients receiving direct-acting antiviral
 treatment
Inclusion Criteria:

 -  18 years of age or older

 -  HCV patients treated with direct-acting antiviral treatment

 -  Patients with a prior treatment blood sample

 -  Patients with sustained virological response or virological relapse

 Exclusion Criteria:

 -  HIV or hepatitis B virus (HBV) coinfection